In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile - Wikidata - wikimedia - TriplyDB

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

http://www.wikidata.org/entity/Q33743827

about

Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance New target for inhibition of bacterial RNA polymerase: 'switch region'Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection Recent developments in antibacterial drug discovery: microbe-derived natural products--from collection to the clinic.Challenges of antibacterial discovery Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora.In vitro activity of OPT-80 against Clostridium difficile.Treatment of Clostridium difficile infection: recent trial results.Future novel therapeutic agents for Clostridium difficile infection.Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.Clostridium difficile drug pipeline: challenges in discovery and development of new agents In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004 Models for the study of Clostridium difficile infection.Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.Emerging therapies in the treatment of Clostridium difficile-associated disease.Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile.Sources of novel antibiotics--aside the common roads.Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis.Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.In vitro activities of OPT-80 and comparator drugs against intestinal bacteria SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea.Final Demonstration of the Co-Identity of Lipiarmycin A3 and Tiacumicin B (Fidaxomicin) through Single Crystal X-ray Analysis.Antimicrobial activities of fidaxomicin In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile Efficacy of LFF571 in a hamster model of Clostridium difficile infection.In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin.Role of fidaxomicin for the treatment of Clostridium difficile infection.The ups and downs of drug discovery: the early history of Fidaxomicin.Antibacterial discovery and development--the failure of success?

P2860

Q24632641-2DAB2CA1-115E-4E34-800E-E74C605C5688 Q24634933-85658C9D-DEFC-4EC6-983D-856A89BC3D46 Q24644390-DD594F92-38B5-4D1E-920F-00F32524BA8C Q24655506-D653E3D6-8A0C-4E91-8DCD-AE4A03EB8DBD Q26770175-DE482155-6187-41AA-8788-4143863D0913 Q33234858-6B3A0609-58D2-47E5-A590-6F3D4436FBC6 Q33793074-86C047BD-C51D-4D00-AA26-5491C132F1C3 Q34044442-8C267635-E6B4-4899-AA75-BCF679A49F32 Q34142125-B6E05CF8-D593-4EDB-B9DD-28C1E22D05DF Q34710368-093450E3-2C9D-4B8D-A8E9-A7D286E5283D Q35175136-32939540-3BD9-413F-8D46-5964D44B0D39 Q35364406-C7416107-0B55-444B-9623-BBF96089DD34 Q35677616-2CF08D4E-09DB-44D3-837D-9FF3C066D285 Q35846436-52D91629-83C6-480D-9A9E-15615FA419D4 Q35912682-54EA494D-1112-4BBE-B2F1-5E0F679D8316 Q36019356-362EF611-BB19-42AD-8FCE-D78663324251 Q36071504-F61E6CC1-79FB-4430-9BA5-A326F9DD984E Q36538752-9B9A4D1E-173E-4041-AE19-AF968E2DF678 Q36659957-9679AC83-7FDF-498E-AD89-E4B6FA83BF69 Q37032807-95BC7E94-35CC-4827-A84E-0F2CC3667B3C Q37544607-3CB28E52-9F19-4DBF-B2D0-2192A8651924 Q37743525-1BC8B84D-AD49-4978-924F-C2708B3AB2C8 Q37779102-93D0999E-ADED-4AC4-A1BC-A3862F236AA9 Q37791857-1492030A-FD8A-441C-9CB3-FFEA7F6A50E2 Q37933407-E85A61B7-B6C7-42B7-ACEC-9EC78532E76D Q38719092-FD92391F-77B1-4928-A3A4-CC4A477CA0F5 Q40121761-1DBC786D-11F2-4200-815E-2FA658887676 Q40290996-F0F143A3-08BC-414A-9129-83775FB81EA8 Q40426045-5BD4FBDD-2AEB-4C02-B40A-B91A57AA906E Q41148853-A9A5AB0E-1435-4A23-9F86-C92A908314B3 Q41415171-733A2644-8267-4108-B374-9D903FF3DE54 Q41860568-5C5C9117-4DA6-4E0A-B714-334C955B0805 Q42222510-15E3A2A0-EFC0-46F4-9076-9D72C24AA871 Q42261294-C4611009-C19E-40D7-9A2C-4BE1900384A8 Q42280743-9605A689-E4D0-428C-8682-7A9E3138D564 Q42695041-B9476E32-CDD6-4BB1-B55B-66DC70B58CC4 Q43181805-C9D2F996-01D8-476F-81E7-733990D00DA4 Q44579640-786C5B5A-DD9D-4C66-AA71-CEB7DAB17A82 Q47589257-A5AFDBA9-18EB-428B-8813-5D5D1E66B2DF Q47825932-00116E80-7EBB-404A-AF10-2610E5730A66

P2860

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

http://www.wikidata.org/entity/Q33743827

description

1991 nî lūn-bûn

@nan

1991 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1991 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

name

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

@ast

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

@en

type

label

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

@ast

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

@en

prefLabel

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

@ast

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

@en

P1433

Q33743827-7A19167D-2457-4621-82E8-B632767E6A44

P1476

Q33743827-C90E4362-0144-4FCD-8C1F-62CCE6A85E30

P2093

Q33743827-27533404-006C-4EA5-9760-0B946BF6C118

Q33743827-8822A6FA-2A32-4622-88E1-01E6E065FB4C

Q33743827-883198A4-B0C9-4EBE-9739-C9AA32B0E877

Q33743827-A5EA50A7-50A5-4E1B-A959-6C3C2F37439F

Q33743827-F31F2EBE-D751-4EAA-8A60-CB0A8CB9BEF8

Q33743827-F65A8131-2273-4A95-9F77-59984F64F4FA

Q33743827-F98C2904-A229-48D3-82B9-7A974663B4FD

P2860

Q33743827-02968555-7698-4D6D-A148-1BFA5B279B77

Q33743827-10F86BE6-4873-4FF7-9EE3-718866411B90

Q33743827-23D89C45-BEC2-436C-87F2-73271B159916

Q33743827-88EF1195-E44B-4FD8-8C51-33E13A7F5B3E

Q33743827-AFF1F40A-E281-4220-83FE-AF5A6B87F4E9

Q33743827-E0EF4B8B-FD5C-48FA-B631-280C7B37FF43

Q33743827-E86D5D57-E4F8-4384-9DD2-523237914CA8

P304

Q33743827-F02CD01C-7FF6-493F-AB73-89795C2BEAB4

P31

Q33743827-FB796F8E-FEDD-4F71-8EEC-B4D4F2A8F736

P356

Q33743827-F5D6C07D-E2F9-488E-AADC-323CE3E4731A

P407

Q33743827-3B958722-B68C-4973-A57F-D90F67AC886A

P433

Q33743827-9EEEA015-30A9-4070-B94A-D4B6B1720668

P478

Q33743827-05D669AC-034F-427C-9B8C-B452F20915C8

P577

Q33743827-CA094818-78F3-4C4E-96FA-5F55CABB718F

P698

Q33743827-B39B9FEA-211B-4E83-B3BF-B007E66290AF

P921

Q33743827-B929029C-1A07-4880-A3CD-2763A16AD867

P932

Q33743827-FA39031B-AC76-42EC-8D33-96852AB0653E

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

@en

P2093

Clement JJ

http://www.w3.org/2001/XMLSchema#string

Fernandes PB

http://www.w3.org/2001/XMLSchema#string

Hanson CW

http://www.w3.org/2001/XMLSchema#string

Hardy DJ

http://www.w3.org/2001/XMLSchema#string

Ramer NC

http://www.w3.org/2001/XMLSchema#string

Shipkowitz NL

http://www.w3.org/2001/XMLSchema#string

Swanson RN

http://www.w3.org/2001/XMLSchema#string

P2860

Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies.

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Genetic characterization of a Clostridium difficile erythromycin-clindamycin resistance determinant that is transferable to Staphylococcus aureus

Management of antibiotic-associated pseudomembranous colitis.

Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032.

Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity.

Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization.

P304

1108-1111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.35.6.1108

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

1991-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1929250

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile

P932

284295

http://www.w3.org/2001/XMLSchema#string